Carna Biosciences (4572) Earnings: Net Sales Increase by +59.8% YoY, Operating Loss Reported at 954 Million Yen

Carna Biosciences (4572) has released its financial results, reporting net sales of 401 million yen, representing a year-on-year increase of +59.8%. However, the company posted an operating loss of 954 million yen, an ordinary loss of 1,005 million yen, and a net loss attributable to owners of the parent of 1,039 million yen. Earnings per share (EPS) stood at -53.13 yen.

From a financial structure and valuation perspective, as of June 30, 2026, the equity ratio was -23.9% and retained earnings were approximately -3.020 billion yen, highlighting challenges in capital stability. As of June 30, 2026, bonds were approximately 1.734 billion yen and convertible bonds with share acquisition rights were approximately 231.249 million yen. Regarding profitability and efficiency metrics, the Return on Equity (ROE) is recorded at 195.46%, while the Return on Assets (ROA) is -23.18%. Market participants will closely monitor future earnings recovery and balance sheet improvements.

---

Correction (September 19, 2026)：The affected figures and reporting-period labels were corrected after checking the source disclosure. Source disclosure